Josef S Smolen

86.2k total citations · 19 hit papers
509 papers, 35.4k citations indexed

About

Josef S Smolen is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Josef S Smolen has authored 509 papers receiving a total of 35.4k indexed citations (citations by other indexed papers that have themselves been cited), including 408 papers in Rheumatology, 136 papers in Hematology and 135 papers in Immunology. Recurrent topics in Josef S Smolen's work include Rheumatoid Arthritis Research and Therapies (313 papers), Systemic Lupus Erythematosus Research (173 papers) and Autoimmune and Inflammatory Disorders Research (128 papers). Josef S Smolen is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (313 papers), Systemic Lupus Erythematosus Research (173 papers) and Autoimmune and Inflammatory Disorders Research (128 papers). Josef S Smolen collaborates with scholars based in Austria, United States and United Kingdom. Josef S Smolen's co-authors include Daniel Aletaha, Paul Emery, Ravinder N. Maini, Joachim R. Kalden, Désirée van der Heijde, Martin Aringer, Marc Feldmann, Klaus Machold, Tanja Stamm and Ferdinand C. Breedveld and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Josef S Smolen

502 papers receiving 34.1k citations

Hit Papers

Infliximab and Methotrexate in the Treatment of Rheumatoi... 1994 2026 2004 2015 2000 2018 1994 1998 2008 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
    2000 2.4k citations Peter E. Lipsky, Désirée van der Heijde et al. profile →
  2. Diagnosis and Management of Rheumatoid Arthritis
    2018 1.5k citations Daniel Aletaha, Josef S Smolen profile →
  3. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
    1994 1.3k citations Josef S Smolen et al. profile →
  4. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
    1998 1.3k citations Ferdinand C. Breedveld, Josef S Smolen et al. Arthritis & Rheumatism profile →
  5. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
    2008 1.1k citations Josef S Smolen et al. profile →
  6. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
    2005 803 citations Daniel Aletaha, Tanja Stamm et al. Arthritis Research & Therapy profile →
  7. A simplified disease activity index for rheumatoid arthritis for use in clinical practice
    2003 795 citations Josef S Smolen, Paul Emery et al. Lara D. Veeken profile →
  8. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.
    2006 661 citations Daniel Aletaha, Josef S Smolen PubMed profile →
  9. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
    2008 624 citations George A. Wells, Josef S Smolen et al. Annals of the Rheumatic Diseases profile →
  10. Range of antinuclear antibodies in “healthy” individuals
    1997 597 citations Josef S Smolen et al. Arthritis & Rheumatism profile →
  11. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial
    1999 570 citations Josef S Smolen, David L. Scott et al. profile →
  12. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
    2006 566 citations Paul Emery, Gianfranco Ferraccioli et al. Annals of the Rheumatic Diseases profile →
  13. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
    2005 502 citations Michael H. Weisman, Josef S Smolen et al. Arthritis & Rheumatism profile →
  14. Baricitinib in Patients with Refractory Rheumatoid Arthritis
    2016 458 citations Stephanie de Bono, Josef S Smolen et al. profile →
  15. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
    2009 423 citations Josef S Smolen, Mittie K. Doyle et al. profile →
  16. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score
    2015 316 citations Daniel Aletaha, Josef S Smolen et al. Annals of the Rheumatic Diseases profile →
  17. 2018 update of the EULAR recommendations for the management of hand osteoarthritis
    2018 308 citations Josef S Smolen, Tanja Stamm et al. Annals of the Rheumatic Diseases profile →
  18. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
    2019 260 citations Josef S Smolen, Paul Emery et al. profile →
  19. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
    2020 195 citations Alexandre Sepriano, Andreas Kerschbaumer et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Josef S Smolen Austria 89 25.5k 10.1k 9.6k 4.0k 3.9k 509 35.4k
Gerd R Burmester Germany 87 15.6k 0.6× 8.8k 0.9× 5.3k 0.6× 3.1k 0.8× 2.6k 0.7× 596 28.3k
Edward Keystone Canada 69 17.0k 0.7× 6.8k 0.7× 7.8k 0.8× 4.2k 1.1× 3.1k 0.8× 404 24.5k
Ronald van Vollenhoven Sweden 80 20.6k 0.8× 10.0k 1.0× 6.8k 0.7× 4.4k 1.1× 3.5k 0.9× 512 27.7k
Yoshiya Tanaka Japan 80 14.5k 0.6× 9.6k 1.0× 5.2k 0.5× 3.8k 1.0× 2.8k 0.7× 1.1k 30.4k
Lars Klareskog Sweden 109 22.1k 0.9× 13.8k 1.4× 5.1k 0.5× 3.7k 0.9× 4.2k 1.1× 657 42.3k
Ben A. C. Dijkmans Netherlands 83 18.3k 0.7× 6.3k 0.6× 6.1k 0.6× 2.1k 0.5× 2.3k 0.6× 332 25.0k
Roy Fleischmann United States 69 16.7k 0.7× 6.4k 0.6× 8.1k 0.8× 3.9k 1.0× 2.4k 0.6× 347 22.9k
Frank C. Arnett United States 67 24.3k 1.0× 9.2k 0.9× 5.6k 0.6× 2.3k 0.6× 7.2k 1.8× 196 37.7k
Joel M. Kremer United States 77 15.2k 0.6× 5.0k 0.5× 6.9k 0.7× 4.1k 1.0× 2.3k 0.6× 322 23.2k
Ravinder N. Maini United Kingdom 80 17.2k 0.7× 10.2k 1.0× 6.0k 0.6× 2.7k 0.7× 2.2k 0.6× 271 31.4k

Countries citing papers authored by Josef S Smolen

Since Specialization
Citations

This map shows the geographic impact of Josef S Smolen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josef S Smolen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josef S Smolen more than expected).

Fields of papers citing papers by Josef S Smolen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josef S Smolen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josef S Smolen. The network helps show where Josef S Smolen may publish in the future.

Co-authorship network of co-authors of Josef S Smolen

This figure shows the co-authorship network connecting the top 25 collaborators of Josef S Smolen. A scholar is included among the top collaborators of Josef S Smolen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josef S Smolen. Josef S Smolen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Kerschbaumer, Andreas, Alexandre Sepriano, Sytske Anne Bergstra, et al.. (2022). Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases. 82(1). 95–106. 90 indexed citations
4.
Leung, Ying Ying, Ana‐Maria Orbai, Maarten de Wit, et al.. (2020). Comparing the Patient‐Reported Physical Function Outcome Measures in a Real‐Life International Cohort of Patients With Psoriatic Arthritis. Arthritis Care & Research. 73(4). 593–602. 10 indexed citations
5.
Dörner, Thomas, Yoshiya Tanaka, Michelle Petri, et al.. (2020). OP0045 DELINEATION OF A PROINFLAMMATORY CYTOKINE PROFILE TARGETED BY JAK1/2 INHIBITION USING BARICITINIB IN A PHASE 2 SLE TRIAL. Annals of the Rheumatic Diseases. 79. 29–30. 1 indexed citations
6.
Tuyl, L. van, Sarah Hewlett, B. Davis, et al.. (2016). The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. Annals of the Rheumatic Diseases. 76(5). 855–861. 67 indexed citations
7.
Tuyl, L. van, B. Davis, Caroline Flurey, et al.. (2015). Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. The Journal of Rheumatology. 43(1). 203–207. 18 indexed citations
8.
Reinisch, Walter & Josef S Smolen. (2015). Biosimilar safety factors in clinical practice. Seminars in Arthritis and Rheumatism. 44(6). S9–S15. 35 indexed citations
9.
Leuchten, Nicolai, et al.. (2014). Relevant Concepts of Functioning for Patients With Systemic Lupus Erythematosus Identified in a Delphi Exercise of Experts and a Literature Review. Arthritis Care & Research. 66(12). 1895–1904. 5 indexed citations
10.
Béresniak, Ariel, Jürgen Braun, Paolo Angelo Cortesi, et al.. (2012). Treat-to-Target in Rheumatoid Arthritis: Clinical and PharmacoEconomic Considerations. Clinical and Experimental Rheumatology. 30. 3 indexed citations
11.
Huizinga, T., P. Emery, René Westhovens, et al.. (2011). Rate of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Seroconversion in Patients with Undifferentiated Arthritis or Early Rheumatoid Arthritis Treated with Abatacept.. Data Archiving and Networked Services (DANS). 63(10). 2 indexed citations
12.
Hayer, Silvia, Birgit Niederreiter, Ionela‐Mariana Nagelreiter, Josef S Smolen, & Kurt Redlich. (2010). Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis. Annals of the Rheumatic Diseases. 69(7). 1403–1406. 17 indexed citations
13.
Smolen, Josef S & Daniel Aletaha. (2009). Developments in the clinical understanding of rheumatoid arthritis. Arthritis Research & Therapy. 11(1). 204–204. 52 indexed citations
14.
Wordsworth, P, Josef S Smolen, Mittie K. Doyle, et al.. (2009). GOLIMUMAB, A HUMAN TNF-ALPHA mu ONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS PREVIOUSLY TREATED WITH ANTI-TNF-ALPHA AGENTS (GO-AFTER STUDY). Lara D. Veeken. 48. 1 indexed citations
15.
Aringer, Martin, W. Graninger, G Steiner, & Josef S Smolen. (2004). Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: An open‐label study. Arthritis & Rheumatism. 50(10). 3161–3169. 256 indexed citations
16.
Galeazzi, Mauro, Gian Domenico Sebastiani, Gabriella Morozzi, et al.. (2002). HLA Class II DNA Typing in a Large Series of European Patients with Systemic Lupus Erythematosus. Medicine. 81(3). 169–178. 33 indexed citations
17.
Heijde, Désirée van der, Lee S. Simon, Josef S Smolen, et al.. (2002). How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. Arthritis Care & Research. 47(2). 215–218. 121 indexed citations
18.
Sebastiani, Gian Domenico, M. Galeazzi, Anǵela Tincani, et al.. (1999). Anticardiolipin and antibeta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology. 28. 344–351. 4 indexed citations
19.
Erlacher, Ludwig, W. Graninger, Frank P. Luyten, Josef S Smolen, & Robert L. Ullrich. (1999). Zellbiologie des Chondrozyten im Hinblick auf die Arthroseentstehung: Rolle der knorpelspezifischen Wachstumsfaktoren Cartilage-Derived Morphogenetic Proteins. Journal für Kardiologie (Krause & Pachernegg GmbH). 6(2). 6–10. 1 indexed citations
20.
Scott, David L., G S Panayi, Piet L. C. M. van Riel, Josef S Smolen, & L. B. A. van de Putte. (1993). Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research.. PubMed. 10(5). 521–5. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerd R Burmester Breakdown of academic impact, for papers by Edward Keystone Breakdown of academic impact, for papers by Ronald van Vollenhoven Breakdown of academic impact, for papers by Yoshiya Tanaka Breakdown of academic impact, for papers by Lars Klareskog Breakdown of academic impact, for papers by Ben A. C. Dijkmans Breakdown of academic impact, for papers by Roy Fleischmann Breakdown of academic impact, for papers by Frank C. Arnett Breakdown of academic impact, for papers by Joel M. Kremer Breakdown of academic impact, for papers by Ravinder N. Maini
Rankless by CCL
2026